VEGF receptor tyrosine kinase inhibitors

Details VEGF receptor tyrosine kinase inhibitors VEGF receptor tyrosine kinase inhibitors

2005-04-12

2005-04-12

Desai, Rita (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S172000, C546S176000, C546S152000

Reexamination Certificate

active

06878720

ABSTRACT:
Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9and R10are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1is aryl; R2is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2cannot represent 2-phthalimidyl; any of R3, R4, R5and R6, independently of the other, is H or a substituent other than hydrogen; and R7and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

REFERENCES:
patent: 3226394 (1965-12-01), Schipper
patent: 19830430 (2000-01-01), None
patent: 0 947 500 (1999-10-01), None
patent: 1189719 (1970-04-01), None
patent: 56-161362 (1981-12-01), None
patent: 9-59236 (1997-03-01), None
patent: 9059236 (1997-03-01), None
patent: 10-259176 (1998-09-01), None
patent: 9525723 (1995-09-01), None
patent: 9609294 (1996-03-01), None
patent: 9641795 (1996-12-01), None
patent: WO 9817648 (1998-04-01), None
patent: 9817648 (1998-04-01), None
patent: 9932477 (1999-07-01), None
patent: 9954284 (1999-10-01), None
The Condensed Chemical Dictionary, Fifth Edition p. 114, 1956.*
Japan Tobacco Inc., Chemical Abstracts, 1982: 162351, (JP 56-161362, Dec. 11, 1981).
Inaba et al., Chemical Abstract 129:310895, Jun. 4, 1999, (JP 10-259176, Sep. 29, 1998).
Augustin, TiPS, vol. 19, “Antiangiogenic tumour therapy: will it work?” pp. 216-222, (Jun. 1998).
Hisano et al., Chem. Pharm.Bull., vol. 20, No. 12, “Syntheses and Pharmacological Activities of 2-Heterocyclic Substituted 4(3H)-Quinazolinone Derivatives,” pp. 2575-2584, (1972).
Lüddens et al., European Journal of Pharmacology, vol. 344, “Structure—activity relationship of furosemide-derived compounds as antagonists of cerebellum—specific GABAAreceptors,” pp. 269-277, (1998).
Caplus, English Abstract JP9059236, Kawagoe Keiichi, Mar. 1997.
Breier et al., Trends in Cell Biology, vol. 6, “The Role of Vascular Endothelial Growth Factor in Blood Vessel Formation,” pp. 454-456, (Dec. 1996).
Mikhailitsyn et al., Chemical Abstracts, vol. 116, 41373f, p. 771, (1992) XP-002128306.
Shani et al., Pharmacology, vol. 26, “Structure Activity Correlation for Diuretic Furosemide Congeners,” pp. 172-180, (1983).
Tiwari et al., J.Chem.Soc.Pak, vol. 4, No. 2, “Visible Antifertility Compounds—Part IV: Syntheses of 2- (Phthalimido methylamino)-substituted benzanilides,” pp. 115-117, (1982).
Varnavas et al., Pharmazie, vol. 51, “Anthranoyl-anthranilic acid: a template for the development of a new class of cholecystokinin receptor ligands,” pp. 697-700, (1996).
The Condensed Chemical Dictionary, Fifth Edition, p. 114 (1956).

Affiliated with

Also associated with

Rating

VEGF receptor tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with VEGF receptor tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGF receptor tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3424581